Skip to main content

Table 8 Real world trial data comparison

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

 

mPFS (mo)

mOS (mo)

DCR (CR + PR + SD) (%)

SAX real world

7.14

15.5

70.6

Spanish real world

4.4

10.8

65.7

France real world

8.3,

16.4,

72

AXIS

6.5

15.2

69.3

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us